Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Myovant Sciences Ltd. (MYOV)

NYSE - NYSE Delayed Price. Currency in USD
26.91+0.12 (+0.45%)
At close: 04:00PM EST
26.88 -0.03 (-0.11%)
After hours: 05:12PM EST
Advertisement

Myovant Sciences Ltd.

11-12 St. James’s Square
Suite 1, 3rd Floor
London SW1Y 4LB
United Kingdom
44 20 7400 3351
https://myovant.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees579

Key Executives

NameTitlePayExercisedYear Born
Mr. David C. MarekCEO & Director1.43MN/A1965
Mr. Uneek MehraPrincipal Financial Officer631.36kN/A1972
Ms. Lauren MerendinoChief Commercial Officer643.23kN/A1975
Mr. Matthew Lang J.D.Gen. Counsel & Corp. Sec.N/AN/A1976
Mr. Albert LiaoDirector of Corp. CommunicationsN/AN/AN/A
Mr. Bryan SelbySr. VP of Product Devel.N/AN/AN/A
Dr. Juan Camilo Arjona Ferreira M.D.Chief Medical OfficerN/AN/A1970
Dr. Andria Langenberg M.D.Head of Drug Safety & PharmacovigilanceN/AN/A1957
Mr. Jeffrey D. NornholdSr. VP of Pharmaceutical Operations & Devel.N/AN/A1966
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

Corporate Governance

Myovant Sciences Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement